A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

NCT ID: NCT07158775

Last Updated: 2025-09-08

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-11-30
• Study Completion Date: 2031-12-31

Brief Summary

This is a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-escalation study; Part 2 is a dose-expansion study with dose(s) selected from Part 1 based on a benefit/risk assessment, and an untreated (sham injection) group to allow for a controlled comparison of efficacy and safety.

This is a seamless Phase 1/2 study in up to 10 patients for Phase 1 and 30 patients Phase 2 in patients with GA secondary to dry AMD.

Conditions

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

BS01 (low dose)

Group Type: EXPERIMENTAL

BS01

Intervention Type: BIOLOGICAL

a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)

Sham control

Group Type: SHAM_COMPARATOR

Sham procedure control

Intervention Type: OTHER

Sham procedure without needle

BS01 (high dose)

Group Type: EXPERIMENTAL

BS01

Intervention Type: BIOLOGICAL

a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)

Interventions

BS01

a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)

Intervention Type: BIOLOGICAL

Sham procedure control

Sham procedure without needle

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent obtained before screening.

2. Men or women between 50 and 85 years of age inclusive at the time of signing the informed consent.

1. Geographic atrophy with some macula foveal involvement secondary to dry AMD.

2. Total GA area ≥ 5 and ≤ 17.5 mm2 (2 and 7 disk areas respectively), based on Heidelberg Region Finder or equivalent automated software.

3. If GA is multifocal, at least one focal lesion should measure ≥ 1.25 mm2 (0.5 disk area) to ensure measurable focal effects for efficacy evaluation.

4. Composite lesion encompassing confluent GA regions with total area meeting thresholds given in 2 above.

5. GA in part within 1200 microns from the foveal center.

6. The atrophic lesion must be able to be photographed in its entirety.

7. BCVA between 20/50 to 20/400, inclusive, using letter score per EDTRS chart.

8. Clear ocular media and adequate pupillary dilatation in both eyes to allow for all imaging procedures, including good quality stereoscopic fundus photography and fundus autofluorescence (FAF).

9. Central fixation.

Exclusion Criteria

1. Previous therapeutic radiation in the region of the SE.

2. Previous treatment with any ocular or systemic gene transfer product.

3. Any treatment with an investigational agent in the past 60 days for any condition.

4. Women who are pregnant or nursing.

5. Known hypersensitivity to topical ocular anesthetics or diagnostic drops to be used during the study.

6. Any other medical condition, which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results.

1. > 30% difference of BCVA using EDTRS in two baseline visual acuity assessments with at least 14 days apart during screening.

2. Any intraocular surgery or thermal laser within 3 months of study entry. Any prior thermal laser in the macular region, regardless of indication.

3. Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks.

4. History of any of the following procedures: Posterior vitrectomy, filtering surgery (e.g., trabeculectomy), glaucoma drainage device, corneal transplant, or retinal detachment.

5. Any sign of diabetic retinopathy in either eye.

6. Intraocular pressure (IOP) > 25 mmHg in either eye.

7. Completely atrophic centrally located lesions based on ellipsoid zone (EZ) loss in spectraldomain optical coherence tomography (SD-OCT).

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bionic Sight LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Sheila Nirenberg, PhD+

Role: CONTACT

snsheilan@gmail.com

1+9178425027

Other Identifiers

BS01-GA-001

Identifier Type: -

Identifier Source: org_study_id